Best Biopharma Outsourcing Companies in Barcelona, Spain
The 41 best Biopharma Outsourcing companies in Barcelona, Spain in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: UQUIFA Group.
Our analysis of 100 Biopharma Outsourcing companies
$10.3b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Biopharma Outsourcing companies in Barcelona
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | UQUIFA Group CDMO company manufacturing APIs and intermediates | $42M | 17 mo ago | Acquired | — | 1936 | WordPressMySQLPHP+23 | — | — |
| 2 | Leanbio Manufacturer of biopharmaceutical product in immunotherapy | $6M | 28 mo ago | Acquired | Andreu Soldevila CEO | 2014 | WordPressMySQLPHP+16 | 10 patents Liposomal formulations for targeted enzyme delivery in therapeutic applications | — |
| 3 | ZeClinics Provider of CRO developing zebrafish models for toxicity studies | $5M | 47 mo ago | Funding Raised | — | 2013 | WordPressMySQLPHP+24 | 3 patents Biomaterial-based tissue regeneration methods and related cell culture technologies. | 1 launch · 1 expansion |
| 4 | Nanoligent Provider of preclinical services for the development of oncology drugs | $2M | 10 mo ago | Series A | M Rodriguez Co-Founder | 2017 | — | 8 patents Nidogen-based scaffold protein nanoconjugates for targeted therapeutic drug delivery | — |
| 5 | Biointaxis Biotechnology company that offers pre-clinical research and gene therapy products | $2M | 22 mo ago | Funding Raised | — | 2017 | — | — | — |
| 6 | Nanomol Technologies Provider of particle design, nanoformulation technologies, and cGMP particle characterization services | $2M | 44 mo ago | Funding Raised | Santi Sala Vergés Co-Founder & CEO | 2010 | — | 3 patents Lipid-based vesicle formulations for enzyme delivery and glucose-derived surfactant systems | 1 partnership |
| 7 | Science4Tech Provider of trial designing, launch, enrollment & feedback services for pharmaceutical industry | $2M | 50 mo ago | Seed | Jordi Guitart CEO | 2019 | — | — | — |
| 8 | Specipig CRO Specializing in Swine Models | $605K | 125 mo ago | Seed | Jaume Amat Riera CEO | 2013 | — | — | — |
| 9 | AtG CRO focused on providing drug discovery and development services to metabolic disease | $568K | 49 mo ago | Seed | Oriol Casanovas Co-Founder | 2021 | — | — | 1 job opening |
| 10 | MedBioInformatics Solutions Provider of NLP and AI solutions for life science data analysis. | $429K | 63 mo ago | Funding Raised | Janet Piñero Co-Founder | 2010 | WordPress Block EditorWordPressMySQL+20 | — | — |
| 11 | Nostrum Biodiscovery Manufacturer of drug discovery and development services | $141K | 92 mo ago | Funding Raised | Modesto Orozco Co-Founder | 2016 | WordPressMySQLPHP+25 | 2 patents Patents concentrated in chemistry & materials | 2 awards |
Top 12 Biopharma Outsourcing companies in Barcelona
#1
Acquired · Barcelona, Catalonia · founded 1936 · 28 employees$42.5Mraised▾
CDMO company manufacturing APIs and intermediates. It supports customers through its new chemical entity programs from pre-clinical stages to commercial production. It also offers comprehensive chemical manufacturing capabilities such as hydrogenation, chlorination, and micronization.
#2
Series A · Barcelona, Catalonia · founded 2017 · 9 employees$2.5Mraised▾
Provider of preclinical services for the development of oncology drugs
- Oct 2025Series A$13.9M
- Sep 2022Seed—
- Feb 2022Seed$1.1M
#3
Funding Raised · Barcelona, Catalonia · founded 2017 · 7 employees$2.4Mraised▾
Developer of genomic treatments and technologies intended for neurological diseases. The company develops innovative gene therapy for the treatment of Friedreich's ataxia, a rare neurological disease, enabling patients with Friedreich's ataxia, a rare neurodegenerative disease for which there is currently no treatment.
- Oct 2024Grant (prize money)$2.3M
- Jul 2023Grant (prize money)$81.9K
#4
Acquired · Barcelona, Catalonia · founded 2014 · 15 employees$6.3Mraised▾
Manufacturer of biopharmaceutical product in immunotherapy. The company has developed recombinant protein in E. coli, CHO mammalian cell line, P. pastoris and S. cerevisiae. The company has developed a platform for upstream (USP) and downstream (DSP) of microbial and mammalian cell cultures and purification of a biotherapeutics. It also developed a platform for the analysis and formulation of protein therapeutics.
- Apr 2024Angel$6.3M
- Mar 2021Grant (prize money)$1.7M
#5
Funding Raised · Barcelona, Catalonia · founded 2013 · 38 employees$5.2Mraised▾
Provider of CRO developing zebrafish models for toxicity studies. The company is supported by University Pompeu Fabra (UPF) and incubated at Barcelona Biomedicine Research Park (PRBB). Services offered by the company include toxicity, efficacy, and genesis assay on zebrafish (using CRISPR/Cas9 technology). Their proprietary models have been licensed by Harvard, MIT, and Broad Institute.
- Oct 2022Grant (prize money)$108.2K
- Jan 2020Grant (prize money)$502K
- Oct 2019Grant (prize money)$274.4K
- Jun 2019Grant (prize money)$180.2K
#6
Funding Raised · Barcelona, Catalonia · founded 2010$2.3Mraised▾
Provider of particle design, nanoformulation technologies, and cGMP particle characterization services. It delivers advanced solutions and technologies to obtain high-added value products through particle design and nanoformulation. It is active in collaborative projects, applying micro and nanotechnology to biomedical and healthcare purposes. The company offers contract analysis on particle characterization, providing high-added value and cGMP services for various materials. The DELOS platform is used for nanoformulation and drug delivery, adding value to drugs and healthcare products.
- Jan 2023Grant (prize money)$523.1K
- Oct 2021Grant (prize money)$26.7K
- Mar 2021Grant (prize money)$1.1M
- Dec 2017Grant (prize money)$149.9K
#7
Seed · Barcelona, Catalonia · founded 2019 · 39 employees$2.1Mraised▾
Developer of a digital platform designed to accelerate the results of clinical trials for the benefit of patients. The company's services collect data from all stages and agents involved in the clinical trial process, and they provide value-added services supported by data-driven SaaS technology and application to improve clinical testing stages under strict scientific rigor and in compliance with regulatory framework, enabling physicians and other healthcare professionals to store information collected from multiple sources and transform data into potent dashboards for decision-making.
- 2022Seed$2.1M
#8
Seed · Barcelona, Catalonia · founded 2021 · 5 employees$567.8Kraised▾
Developer of novel classes of drugs and biomarkers intended to prevent cancer therapeutic resistance. The company specializes in the discovery and development of new therapeutic technologies for cancer resistance including biomarkers, drugs, and novel mechanisms, enabling health practitioners to improve the lives of patients affected by cancer therapeutic resistance.
- Jul 2022Seed$567.8K
#9
Funding Raised · Barcelona, Catalonia · founded 2020 · 16 employees$81.9Kraised▾
Provider of transcriptomic tests that focused on reversing aging. It offers a blood test that analyzes the RNA levels to examine the expression of all genes in the genome associated with different metabolic pathways.
- Jul 2023Grant (prize money)$81.9K
#10
Funding Raised · Barcelona, Catalonia · founded 2010 · 9 employees$428.6Kraised▾
Provider of NLP and AI solutions for life science data analysis. It offers services in data analytics and semantic integration to unlock data's potential. The company develops solutions using AI, knowledge graphs, and NLP to accelerate product development. It provides access to data on disease genomics to speed up drug R&D and precision medicine. The company also offers a gene-disease database, facilitating access to information for researchers.
- Jun 2021Grant (prize money)$428.6K
#11
Seed · Barcelona, Catalonia · founded 2013 · 18 employees$605.1Kraised▾
Specipig is a CRO specialising in model pigs. It is currently the only company in Europe to offer comprehensive services for biomedical research with this animal model, which include breeding of genetically selected pigs, an analytical laboratory, an operating room and a team of experts in toxicology and proof of concept for new drugs, validation of medical devices, surgical training and research into new surgical techniques. In collaboration with the Government of Catalonia Institute for Research and Technology in Food and Agriculture (IRTA), Specipig is developing its own genetic breed of miniature pigs (which weigh 35 kgs as compared to conventional pigs which weigh 200 kgs approx.), which will be marketed in the near future. They also have conventional Specific Pathogen Free pigs.
- Mar 2016Seed$605.1K
- 2014Venture Debt$265.8K
#12
Funding Raised · Barcelona, Catalonia · founded 2016$141.4Kraised▾
Manufacturer of drug discovery and development services
- Jan 2019Grant (prize money)$141.4K
- Dec 2018Grant (prize money)—
- Jan 2018Grant (prize money)—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Biopharma Outsourcing coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology in Barcelona is moving
A read on the academic research around Biotechnology in Barcelona — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 67 papers.
- Universitat Autònoma de Barcelona25
- Universitat de Barcelona23
- Hospital Clínic de Barcelona7
- Barcelona Institute for Global Health5
- Instituto de Investigaciones Químicas y Ambientales de Barcelona3
- Detection limit2
- Context (archaeology)2
- Mycotoxin2
- microRNA1
- Microvesicles1
- Replication (statistics)4
- Fermentation3
- Thermophile2
- Raw material2
- Bioprocess2
- Antimicrobial1→3
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.